Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)

Launched by YALE UNIVERSITY · May 11, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at two different approaches to help people with Crohn's disease who also struggle with anxiety and depression. The study is comparing Cognitive Behavioral Therapy (CBT), which is a type of talk therapy that helps change negative thought patterns, to Sudarshan Kriya Yoga (SKY), a breathing technique that promotes relaxation. Researchers want to see which method is more effective at improving mental health in patients with Crohn's disease.

To participate, individuals must have a confirmed diagnosis of Crohn's disease and be on a steady treatment plan without signs of active inflammation. They also need to show symptoms of anxiety or depression based on specific questionnaires. Participants will continue their current medications for these conditions during the study. It's important to note that people with severe mental health issues or active intestinal inflammation will not be eligible to join. If you or someone you know is considering this study, it could be a valuable opportunity to improve mental well-being while managing Crohn's disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • verified inflammatory bowel disease (Crohn's disease and ulcerative colitis)
• • IBD patients on a stable treatment regimen with no evidence of active intestinal inflammation based on either normal c-reactive protein and/or fecal calprotectin, imaging studies, or endoscopy who meet the criteria for anxiety or depression based on the screening questionnaires
• • subjects who have been on stable doses of anxiety and/or depression medications (defined as no dose adjustment in the prior 12 weeks) at the screening visit who meet the criteria for anxiety and/or depression based on screening questionnaires and are willing to stay on the same dose of these medications throughout the study duration
• • may meet the criteria for both anxiety and depression and cohort assignment will be based on the survey with the highest scores suggesting more severe symptoms
• Exclusion Criteria:
• • declines to participate for the full duration of the study
• • evidence of active intestinal inflammation based on an elevated c-reactive protein and/or fecal calprotectin, imaging studies or endoscopy
• • non-English speaker
• • any subject who expresses suicidal ideation or has severe mental illness as they will be taken to the emergency room for urgent psychiatric care